496 related articles for article (PubMed ID: 33995661)
1. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.
Wei X; Song M; Li W; Huang J; Yang G; Wang Y
Theranostics; 2021; 11(13):6334-6354. PubMed ID: 33995661
[TBL] [Abstract][Full Text] [Related]
2. Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR.
Mohammad IS; He W; Yin L
Crit Rev Ther Drug Carrier Syst; 2020; 37(5):473-509. PubMed ID: 33389848
[TBL] [Abstract][Full Text] [Related]
3. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
4. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
6. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
7. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
10. Zinc Oxide Nanoparticles as Adjuvant To Facilitate Doxorubicin Intracellular Accumulation and Visualize pH-Responsive Release for Overcoming Drug Resistance.
Liu J; Ma X; Jin S; Xue X; Zhang C; Wei T; Guo W; Liang XJ
Mol Pharm; 2016 May; 13(5):1723-30. PubMed ID: 27070828
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.
Zhu WJ; Yang SD; Qu CX; Zhu QL; Chen WL; Li F; Yuan ZQ; Liu Y; You BG; Zhang XN
Int J Nanomedicine; 2017; 12():3375-3393. PubMed ID: 28490877
[TBL] [Abstract][Full Text] [Related]
12. Dual-responsive TPGS crosslinked nanocarriers to overcome multidrug resistance.
Li L; Liu T; Liao JX; Zhang ZY; Song DB; Wang GH
J Mater Chem B; 2020 Sep; 8(36):8383-8394. PubMed ID: 32803210
[TBL] [Abstract][Full Text] [Related]
13. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.
Milane L; Ganesh S; Shah S; Duan ZF; Amiji M
J Control Release; 2011 Oct; 155(2):237-47. PubMed ID: 21497176
[TBL] [Abstract][Full Text] [Related]
14. Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.
Ling G; Zhang T; Zhang P; Sun J; He Z
Int J Nanomedicine; 2016; 11():4077-91. PubMed ID: 27601896
[TBL] [Abstract][Full Text] [Related]
15. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
Zhang Q; Li F
Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
[TBL] [Abstract][Full Text] [Related]
16. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
Mohammad IS; He W; Yin L
Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
[TBL] [Abstract][Full Text] [Related]
17. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
Xue X; Liang XJ
Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
[TBL] [Abstract][Full Text] [Related]
18. Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy.
Yang H; Shen X; Yan J; Xie X; Chen Z; Li T; Li S; Qin X; Wu C; Liu Y
Biomater Sci; 2018 Aug; 6(9):2426-2439. PubMed ID: 30040100
[TBL] [Abstract][Full Text] [Related]
19. pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells.
Zhang W; Wang F; Wang Y; Wang J; Yu Y; Guo S; Chen R; Zhou D
J Control Release; 2016 Jun; 232():9-19. PubMed ID: 27072026
[TBL] [Abstract][Full Text] [Related]
20. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery.
Kou L; Sun R; Bhutia YD; Yao Q; Chen R
Expert Opin Drug Deliv; 2018 Sep; 15(9):869-879. PubMed ID: 30169976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
